Alaunos Therapeutics Inc (TCRT)

[$5.95akadawson-m]

That's public knowledge and it has been for quite some time. All of Ziop's investors can't be irrational yet, they need you to tell them something different like "failed candidates." We're are discussing a biotech for pete's sake, which is analogous to a car having flat tires on occasion. The very nature of a biotech is trial and error, but this is what is missing in your argument: what happens if Ziop does create an advantage in its methodology? Like, their ORR goes up and a cancer patient doesn't have to stay over night in a hospital? This is the part that is missing from your presentation and the part that is gaining traction in the marketplace.